Adaptive Optics Retinal Imaging

Description

The objective of the study is to collect and assess adaptive optics (AO) retinal images from human subjects in support of projects to demonstrate, advance, and enhance clinical use of AO technology.

Conditions

Glaucoma, Primary Open Angle

Talk to us

Study Overview

On this page

Study Details

Study overview

The objective of the study is to collect and assess adaptive optics (AO) retinal images from human subjects in support of projects to demonstrate, advance, and enhance clinical use of AO technology.

Adaptive Optics Retinal Imaging

Adaptive Optics Retinal Imaging

Condition
Glaucoma, Primary Open Angle
Intervention / Treatment

-

Contacts and Locations

Silver Spring

Food and Drug Administration, Silver Spring, Maryland, United States, 20993

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Are 21 years of age or older.
  • 2. Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam).
  • 3. Have the ability to understand and sign an informed consent.
  • 4. Have been diagnosed with POAG (cohort 2).
  • 1. Are under 21 years of age.
  • 2. Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity).
  • 3. Have visual correction outside of the range +4 diopters (D) to -8 D.
  • 4. Have a history of adverse reaction to mydriatic drops.
  • 5. Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG).
  • 6. Have any health conditions that would contraindicate oxygen supplementation, including chronic obstructive pulmonary disease (COPD), emphysema, asthma, or any other obstructive or restrictive lung disease (oxygen challenge participants only).
  • 7. Have a dependency on oxygen support or a baseline oxygen saturation \<95% (oxygen challenge participants only).
  • 8. Have tested positive for COVID-19 at initial enrollment or have acute or chronic photophobia as a result of contraction.
  • 9. Are working under the direct supervision of Dr. Hammer.

Ages Eligible for Study

21 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Food and Drug Administration (FDA),

Daniel X Hammer, Ph.D., PRINCIPAL_INVESTIGATOR, Food and Drug Administration (FDA)

Study Record Dates

2026-09-30